Lv1
30 积分 2024-05-10 加入
Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study
20天前
已完结
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
20天前
已完结
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
20天前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
20天前
已完结
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
20天前
已完结
Strength of Genetic Associations with Thyrotropin Values Differs Between Populations with Similarity to African and European Reference Populations
1个月前
已完结
家族性分化型甲状腺癌 131I初次治疗后的疗效分析
2个月前
已完结
Familial nonmedullary thyroid carcinoma—clinical relevance and prognosis. A European multicenter study
2个月前
已完结
Familial Nonmedullary Thyroid Cancer
2个月前
已完结
Familial Nonmedullary Thyroid Cancer
2个月前
已完结
皖公网安备34019202002308
